日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and safety of camrelizumab-based regimens in advanced squamous cell carcinoma patients: a prospective multicenter study

卡瑞利珠单抗治疗方案在晚期鳞状细胞癌患者中的疗效和安全性：一项前瞻性多中心研究

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2026.1767096
Jiang, Weijia; Peng, Wanren; Qian, Dong; Wang, Genhe; Qian, Hong; Deng, Wenxia; Wang, Zishu; Wei, Zhiyong; Ma, Tai; Zhao, Dong; He, Yifu; Li, Chenghui; Wang, Gang; Zheng, Zhongxian; Guo, Xinglai; Zhu, Shaojin; Xia, Liming; Jiang, Xiangde; Wei, Jie; Li, Xinzhong; Sun, Guoping
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Surufatinib plus tislelizumab as later-line therapy for metastatic colorectal cancer: a single-arm, phase II trial

苏鲁替尼联合替雷利珠单抗作为转移性结直肠癌的二线治疗：一项单臂 II 期试验

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-026-15705-z
Xu, Huijun; Yan, Ying; Niu, JiaYu; Cao, Lulu; Chen, Wenju; Li, Mengge; Luo, Huiqin; Ke, Lihong; Wu, Shusheng; Wang, Gang; He, Yifu
肿瘤
肠癌
肿瘤免疫
发表日期：2026
文献求助 收藏

HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma.

HBV DNA整合基因CCDC91具有致癌性，是肝细胞癌的潜在治疗靶点

期刊:Communications Biology
影响因子:5.1
doi:10.1038/s42003-025-08369-1
Li Mengge, Wu Shusheng, Luo Huiqin, Niu Jiayu, Fang Yuan, Chen Wenju, Cao Lulu, He Yifu
细胞生物学
发表日期：2025
文献求助 收藏

Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study

呋喹替尼在中国结直肠癌患者中的安全性：一项来自IV期真实世界临床实践研究的年龄亚组分析

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359251363537
Wang, Yi; He, Yifu; Wang, Zhiqiang; Zhong, Haijun; Niu, Zuoxing; Yang, Shujun; Zhang, Tao; Zhu, Liangjun; Shu, Yongqian; Peng, Jianjun; Song, Yan; Li, Jian; Yuan, Ying; Zhang, Haibo; Yu, Gengsheng; Hua, Yunqi; Xiao, Jianjun; Fu, Jianfei; Zheng, Yulong; Zhu, Jingyu; Xue, Hua; Luo, Xian; Shi, Michael; Su, Weiguo; Li, Jin; Qin, Shukui
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

卡瑞利珠单抗联合阿帕替尼和伊立替康作为晚期或转移性食管鳞状细胞癌患者的二线治疗方案

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14207-8
Wu, Shusheng; Luo, Huiqin; Chen, Wenju; Liu, Xudong; Li, Huimin; Li, Mengge; Ke, Lihong; Niu, Jiayu; Hu, Bing; Xu, Huijun; Wang, Gang; Yan, Ying; Cao, Lulu; Hu, Xiaoxiu; Li, Chenghui; He, Yifu
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A machine learning model utilizing CT radiomics features and peripheral blood inflammatory markers predicts the prognosis of patients with unresectable esophageal squamous cell carcinoma undergoing PD-1 inhibitor combined with concurrent chemoradiotherapy

利用CT放射组学特征和外周血炎症标志物的机器学习模型预测接受PD-1抑制剂联合同步放化疗的不可切除食管鳞状细胞癌患者的预后

期刊:Journal of Cancer
影响因子:3.2
doi:10.7150/jca.105171
Liu, Xudong; Gao, Fei; Wu, Shusheng; Wang, Haoyu; Dang, Wenxi; Sun, Mingjie; Zhang, Zhihua; Li, Mengge; Cai, Zhirun; Li, Wen; He, Yifu
肿瘤
炎症
肿瘤免疫
炎症/感染
细胞生物学
PD-1
发表日期：2025
文献求助 收藏

Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial

伊帕罗利单抗 (QL1604) 用于微卫星不稳定性高 (MSI-H) 或错配修复缺陷 (dMMR) 的不可切除或转移性实体瘤患者：一项关键性、单臂、多中心 II 期试验

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-024-01627-5
Bi, Feng; Dong, Jian; Jin, Chuan; Niu, Zuoxing; Yang, Wenhui; He, Yifu; Yu, Dajun; Sun, Meili; Wang, Teng; Yin, Xianli; Zhang, Ruixing; Chen, Kehe; Wang, Keming; Wang, Zhiwu; Li, Wei; Zhang, Zhongtao; Zhang, Hangyu; Guo, Qunyi; Wang, Xin; Han, Lei; Zhang, Xizhi; Shen, Wei; Zhang, Liangming; Ying, Jieer; Wu, Miao; Hu, Weiguo; Li, Zeng; Li, Xiaofen; Feng, Wenlei; Zhang, Baihui; Li, Lingyan; Kang, Xiaoyan; Guo, Weijian
多发性硬化症
多发性骨髓瘤
发表日期：2024
文献求助 收藏

Identification of hepatitis B virus infection and integration and its oncogenic role in gastric cancer

鉴定乙型肝炎病毒感染和整合及其在胃癌中的致癌作用

期刊:Clinical and Translational Medicine
影响因子:6.8
doi:10.1002/ctm2.1601
Li, Mengge; Wu, Shusheng; Niu, Jiayu; Luo, Huiqin; Chen, Wenju; Cao, Lulu; Yan, Ying; Tu, Hong; He, Yifu
胃癌
肿瘤
肿瘤免疫
炎症/感染
微生物学
肝炎
发表日期：2024
文献求助 收藏

A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice

一项评估呋喹替尼在中国患者真实世界临床实践中安全性的IV期研究

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyae073
Li, Jin; Wang, Zhiqiang; Zhong, Haijun; He, Yifu; Zhang, Chen; Niu, Zuoxing; Yang, Shujun; Zhang, Tao; Zhu, Liangjun; Shu, Yongqian; Gao, Yong; Peng, Jianjun; Song, Yan; Li, Jian; Yuan, Ying; Zhang, Haibo; Yu, Gengsheng; Hua, Yunqi; Xiao, Jianjun; Fu, Jianfei; Zheng, Yulong; Xue, Hua; Luo, Xian; Shi, Ming; Su, Weiguo; Qin, Shukui
发表日期：2024
文献求助 收藏

Association between quantitative CT body composition analysis and prognosis in cetuximab-based first-line treatment for advanced colorectal cancer patients

定量CT体成分分析与以西妥昔单抗为基础的一线治疗晚期结直肠癌患者预后之间的关联

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-13338-8
Dang, Wenxi; Wu, Shusheng; Liu, Xudong; Shen, Hao; Chen, Yaolin; Zhang, Zhihua; Wang, Haoyu; Cai, Zhirun; Li, Mengge; Sun, Mingjie; Gao, Fei; He, Yifu
肿瘤
肠癌
肿瘤免疫
发表日期：2024
文献求助 收藏